IL-1b and its mRNA as well as IL-1Ra mRNA. 5, 18 These substances are also reported to be involved in excitotoxicity, oxidative stress and modulation of neuroendocrine systems.
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Animal studies
Basal levels of IL-1b mRNA and IL-1Ra mRNA are barely detectable in the intact rat brain. 2, 11 However, IL-1b mRNA and IL1b protein expression rapidly increases in the cortex, hippocampus, and hypothalamus following various experimenter-induced seizures. 2, [23] [24] [25] [26] [27] [28] [29] [30] [31] In chronic epilepsy animal model, IL-1b expression is also increased in the cortex and hippocampus. 11, 23, 25, 26, 32, 33 The cortex and hippocampus showed the most extensive postictal neuronal injury. In these animal models, at the cellular level, IL-1b mRNA is first expressed by activated microglia followed by astrocytes. 3 IL-1Ra mRNA is observed in similar regions following induced seizures, but its expression is delayed and not sufficient for complete inhibition of IL-1 effects. 5, 26 Most studies suggest proconvulsive effects for IL-1b. In rodent epilepsy models involving kainic acid, intrahippocampal injection of IL-1b worsened and prolonged both electrographic and behavioral seizure activity. 5, 25 Furthermore, seizure-like behavioral changes induced by whole-cell pertussis vaccine were significantly reduced following inhibition of IL-1b production by the administration of an inhibitor of IL-1b-converting enzyme and were almost completely abrogated in IL-1 receptor knockout mice. 34 Moreover, endogenous IL-1b has been shown to contribute to the development of febrile seizures (FS). 13 As indirect evidence of the proconvulsive effect of IL-1b, intracerebral injection of IL-Ra reduced behavioral convulsions induced by bicuculline methiodide in mice. 5 In transgenic mice overexpressing IL-Ra in astrocytes, the threshold for seizure generation increased. 9 Therefore, the epileptogenic potential of IL-1b appears to be independent of direct neurotoxicity. [35] [36] [37] With respect to proconvulsive mechanisms, IL-1b can not only augment nitric oxide formation to raise seizure susceptibility but can also increase neuronal excitability by: directly inhibiting GABA(A) receptors, increasing NMDA receptor function, and inhibiting K + efflux. 21, [38] [39] [40] [41] The proconvulsive actions of IL-1b also depend on the activation of sphingomyelinase and Src kinases in the hippocampus, which can lead to the phosphorylation of NR2B subunit of the NMDA receptor and evoke neuronal hyperexcitability. 42 A minority of studies imply an anticonvulsant effect of IL-1b. After synaptoneurosomes were incubated with IL-1b in a concentration of 100 pg/ml, 1 ng/ml and 10 ng/ml in vitro, IL-1b was shown to cause GABA-mediated increase in chloride permeability, 38 and intraperitoneal injection of 1 mg IL-1b increased the threshold for pentylenetetrazol-induced seizures in mice. 38 In addition, intraventricular injection of IL-1b (0.01, 0.1, and 10 ng/300-350 g rat) exhibited significant anticonvulsant effects in an amygdala kindling model. 12 In contrast to the proconvulsive mechanisms of IL-1b, the potential anticonvulsive pathways are far from being elucidated. One in vitro study found that IL-1b could increase K + -evoked GABA release without affecting K + -evoked glutamate release when the rise of intracellular Ca 2+ concentration was prevented. 41 This effect may result in a preponderance of GABAergic over glutamatergic transmission. It was also reported that intracellular Ca 2+ concentration was increased by IL-1b in a dose dependent fashion. 43 Thus, the extracellular concentration of IL-1b possibly has an impact on the balance between glutamate and GABA release through its influence on intracellular Ca 2+ concentration. At relatively low levels, IL-1b seems to exert an anticonvulsant effect by limiting intracellular Ca 2+ and enhancing GABAergic transmission, whereas higher concentrations of IL-1b may have proconvulsive effects.
Human studies
In genetic studies, homozygosity for the IL-1b-511 allele 2, which is suggested to be an inducer of IL-1b, was overrepresented in TLE patients with hippocampal sclerosis (HS) when compared to both control subjects and TLE patients without HS. 44, 45 However,
other studies failed to demonstrate any significant difference in genotype and allele frequencies between TLE patients with HS and controls. [46] [47] [48] [49] Likewise, an association between the frequency of the IL-1b-511 allele 2 and an increased risk of febrile convulsions has been reported, 45, 50 however, this association was refuted in another study. 51 The latter study only showed a trend towards an increased frequency and carriage of the putative IL-1b-511 allele 2 in a sub-sample of 43 patients with febrile convulsions who reported a positive family history of seizures in first and/or second degree relatives, but these trends did not reach statistical significance. A possible reason for these contradicting results is a different prevalence of the allele in different ethnicities. Further studies with larger patient populations in different ethnicities are required for unveiling the association between IL-1b-511 allele 2 and epilepsy. Several clinical studies adressed the change of IL-1b levels in blood and cerebrospinal fluid (CSF) of patients with focal epilepsy. There were no significant differences in the IL-1b concentration in blood and CSF within 24 h after tonic-clonic seizures when compared to control subjects. 52 More recent studies in patients with focal epilepsy similarly showed that postictal plasma concentrations of IL-1b after complex partial or secondary generalized tonic-clonic seizures did not significantly differ from baseline levels. 53, 54 However, the levels of IL-1Ra in serum can be increased after a single complex partial or generalized tonic-clonic seizure in patients with various focal epilepsy syndromes. 4 Interictally, elevated IL-1b plasma concentration was seen in patients with focal epilepsy due to benign cerebral tumors or dysplasia. 55 For patients with febrile seizures, there were no significant differences in postictal mean IL-1b levels in either CSF or blood compared to controls, 56 however, Virta et al. found that the plasma IL-1Ra/IL-1 b ratio was the most significant factor connected to FS (OR, 41.5; 95% CI, 4.9-352.8) comparing with plasma IL-1Ra, IL-1b, IL-6, IL-10 and TNFa. 57 Unlike in blood and CSF, an increased expression of IL-1b and its receptor in astrocytes, microglia, and neurons has been documented in brain specimens obtained from patients surgically treated for TLE with HS. 58 IL-1b and its receptor were found to be highly expressed in neurons and glia in patients with intractable epilepsy caused by focal cortical dysplasia and glioneuronal tumors, 3 whereas expression of IL-1b and its receptor in normal brain tissue were negligible. 3, 58, 59 Although the majority of studies demonstrates an increased level of this cytokine in the epileptogenic zone, conclusive evidence for a distinct role of IL-1b in epilepsy has yet to be shown.
Conclusion
Most animal and human studies have found an association between the expression of IL-1b in the brain and seizures or epilepsy. IL-1b plasma levels in patients with epilepsy are low and postictal plasma concentrations of IL-1b after generalized tonicclonic or complex partial seizures did not significantly differ from baseline. [52] [53] [54] Therefore, analyzing the blood of epilepsy patients in clinical studies is not sufficient to assess the function of IL-1b in the pathogenesis of epilepsies. Animal models of epilepsy may be necessary for a more detailed view. A large body of animal experiments supports the epileptogenic potential of high IL-1b concentrations, whereas the intraperitoneal and intraventricular injection of relatively low doses of IL-1b seems to have antiepileptogenic effects. 12, 38 The influence of the extracellular concentration of IL-1b on seizures or epilepsy merits further investigation.
Interleukin-6 (IL-6)
IL-6 is a multifunctional cytokine that regulates inflammatory responses and other immune reactions. 60 
Animal studies
After seizures, IL-6 mRNA is rapidly induced in the hippocampus, cortex, dentate gyrus, amygdala, and meninges, whereas upregulation of IL-6-receptor mRNA seems to be limited to the hippocampus. 11, 66 In rodent models of limbic status epilepticus (SE) induced by kainic acid, bicuculline methiodide, or electrical stimulation, IL-6 mRNA and IL-6 protein were transiently increased in glial cells, with maximal induction occurring 6 h after SE. 5 In another study of a rat SE model induced by lithiumpilocarpine, the expression of IL-6 mRNA peaked between 10 h and 16 h and returned to control levels within 5 days. 66 Conversely, it was at seven days after seizures that gp130 mRNA was upregulated in thalamus, cortex, amygdala, and hippocampus, which showed a delayed reaction when compared to IL-6 mRNA. 11 The rapid increase of IL-6 expression may be associated with membrane depolarization leading to accumulation of IL-6 mRNA and IL-6 protein in neurons. 67, 68 There have been conflicting reports on the influence of IL-6 on seizures in recent years. In developing rats, intra-nasal administration of IL-6 (50 or 500 ng) lengthened the latency and shortened the duration of hyperthermia-induced seizures, which was associated with activation of the adenosine receptor. 69 On the other hand, intranasal administration of IL-6 (400 ng) in adult rats exacerbated the severity of seizures induced by pentylenetetrazole 6 which was demonstrated by shorter latency to SE onset, longer SE duration, and higher mortality. Ambiguous effects of IL-6 on seizure susceptibility were found not only in animals of different developing states, but also in different transgenic animal models. In IL-6 deficient mice, aspartate levels significantly increased in the brain stem and hippocampus, which could be responsible for the increased susceptibility to kainic-acid-induced seizures. 70 Moreover, neuronal injury was increased after kainic acid induced seizures. 70, 71 These findings do not support the view of neuroprotective and anticonvulsive properties of IL-6. However, transgenic mice overexpressing IL-6 exhibit spontaneous tonicclonic seizures, 72 which is possibly related to disrupted cholinergic transmission of hippocampal cholinoceptive target neurons. 8 Another study on transgenic mice overexpressing IL-6 in astrocytes reported an increased sensitivity to seizures induced by glutamatergic agonists (i.e., kainic acid and NMDA) and a constitutive loss of GABA-and parvalbumin-immunoreactive neurons in the hippocampus. 73 These results suggest that reduced GABA-mediated inhibition is responsible for the propensity of these rats to develop seizures. What further confounds the ambiguous nature of IL-6 is that it is necessary for normal development of the nervous system, 74 but an increased level of IL-6 in the brain has neurotoxic and proconvulsive effects. whereas IL-6 receptor plasma levels were slightly decreased or remained unchanged. 4 The increase of IL-6 levels in CSF after generalized tonic-clonic seizures was found to be more pronounced than the increase in plasma. 52, 77, 78 Therefore, IL-6 synthesis was initially thought to occur predominantly within the CNS. However, seizures themselves can activate the sympathetic nervous system (SNS) and induce the release of catecholamines (CAs). [79] [80] [81] [82] [83] Catecholamines have been shown to mediate cytokine release from peripheral blood mononuclear cells (PBMCs). 84 Moreover, PBMCs from epileptic patients showed greater production of IL-6 in response to in vitro stimulation with mitogen as compared to controls. 85 Thus, cytokine release from PBMCs would be another explanation for the postictal increase of IL-6. Other studies suggest a relationship between IL-6 plasma levels and different focal epilepsies. IL-6 was found to be increased in TLE but not in extra-TLE during the interictal stage. 86 At 6 h after complex partial or secondary generalized tonic-clonic seizures in patients with TLE or extratemporal epilepsies, only the TLE group showed a significant rise in plasma levels of IL-6. 53 Previous results from our group showed a rapid increase of IL-6 plasma levels after seizures in patients with TLE without hippocampal sclerosis (HS), whereas this increase was lacking in patients with HS. 54 These findings suggest a possible neuroprotective effect of IL-6 in TLE, which helps to prevent the development of HS, assuming the systemic IL-6 increase reflects similar changes in the mesial temporal region. However, activation of SNS by temporal lobe structures, e.g. hippocampus, and consecutive release of CAs and raise of IL-6 plasma levels cannot be ruled out. In conclusion, the IL-6 level in plasma does not reliably reflect its brain level.
Conclusion
Animal experiments show that a high concentration of IL-6 in the brain is an obvious neurotoxic and proconvulsive factor, especially for the adult brain, although IL-6 is necessary for the normal CNS development. The increased expression of IL-6 both in brain and blood is closely associated with seizures and epilepsy. However, it remains unclear whether elevated blood levels of IL-6 allow a conclusion to be drawn about the expression and function of IL-6 in epileptogenic brain areas. In vivo studies on IL-6 expression in the human brain are difficult to perform for the obvious reason of limited access to brain tissue from the epiletogenic zone. Animal models that closely resemble certain epilepsy syndromes and allow a fractionated analysis of epiletogenesis are required.
TNFa
In the CNS, TNFa can activate its two receptors (p55 and p75) and may modulate cell-signaling pathways. 87, 88 The p55 receptor has been implicated in the activation of programmed cell death, whereas p75 receptors are associated with activation of the nuclear factor Kappa B (NF-kB) system.
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Animal studies
After seizures evoked by amygdala kindling in rats, TNFa mRNA levels showed a significant up-regulation in the parietal, prefrontal, and piriform cortex, as well as in the amygdala and hippocampus, 2,92 which returned to baseline within 3 weeks. 2 Limbic SE in rodents also rapidly and transiently enhanced TNFa mRNA in the hippocampus with a peak effect at 6 h. 5 TNFa plays a dichotomous role in epilepsy. Intrahippocampal injection of murine-recombinant TNFa (2.5 and 15.0 pmol/25 g mouse) potently inhibited seizures in mice. 7 Transgenic mice with astrocytic overexpression of TNFa revealed shorter seizures whereas mice lacking TNFa receptors showed prolonged seizures. 7 In contrast, transgenic mice expressing TNFa in neurons throughout the brain developed seizures and died prematurely. 93 Intraperitoneal injection of TNFa (5.0 mg/kg) prolonged the duration of epileptiform discharges in amygdala-kindled rats. 94 In a computational model of neuron-glia interaction in TNFamediated synaptic scaling, TNFa overexpression by glia induced seizure-like activity suggested that TNFa diffusion may be responsible for epileptogenesis after localized brain lesions. 95 The pro-and anti-convulsive effects of TNFa may be derived from activation of its different receptors in the brain, p55 and p75. Balosso et al. found that the anticonvulsant activity of TNFa in mice was mediated by the neuronal p75 receptor. 7 In the same study, p75 receptor knockout mice displayed enhanced seizure activity, whereas p55 receptor knockout mice had reduced seizure susceptibility. 7 In another report, TNFa changed the molecular stoichiometry of synaptic AMPA receptors and increased excitatory synaptic activity through interactions with p55 receptors. 96 P55
signaling through apoptosis signal-regulating kinase 1 might be a key event in the death of neurons following seizures. 97 These findings suggest that the p55 pathway is involved in proconvulsive and neurotoxic effects of TNFa in animal models of epilepsy and that the p75 pathway is associated with anticonvulsive effects. However, the mechanisms responsible for the preponderance of the p55 pathway over the p75 pathway or vice versa are still unclear.
Several studies indicate that TNFa possibly acts in a concentration-dependent manner. TNFa has been shown to play a proconvulsive role in Shigella-mediated seizures at low concentrations, but exerted an anticonvulsive effect at higher concentrations. 98 In addition, it was also reported that picomolar in vitro concentrations of TNFa could efficiently trigger the p55 pathway, whereas activation of p75 required significantly higher concentrations. 99 Therefore, low concentrations of TNFa may predominantly activate proconvulsive effects via p55 while high concentrations of TNFa can play an anticonvulsive role through the p75 pathway.
Human studies
There are little data on TNFa in patients with epilepsy. No significant changes of TNFa have been found in plasma or CSF in patients within 24 h after acute tonic-clonic seizures or partial secondarily generalized seizures. 52, 54 There were also no significant changes of TNFa in plasma or CSF of patients with febrile seizures. 57, 100 Studies on the intracerebral expression of TNFa in these patients are lacking.
Conclusion
In animal models, seizures can induce the expression of TNFa mRNA in brain although its mechanism and relevance remain elusive. Animal studies have clearly demonstrated that TNFa plays a dichotomous role in seizures depending on the activation of different downstream receptors, which possibly is related to its extracellular concentration. However, due to absence of clinical studies, these conclusions have not yet been verified in humans.
Other cytokines
IL-2
IL-2 plays an important role in regulating the immune response, particularly through T-cell activation. 101, 102 Intraventricular administration of IL-2 in DBA/2 mice promotes seizure generation in various models of experimental epilepsy, including sound-and chemoconvulsant-induced seizures. 103 However, IL-2 levels in plasma and CSF remained unchanged in patients with prolonged febrile seizures, with or without encephalopathy, during the acute stage. 104 
IL-10
IL-10 has broad anti-inflammatory properties by its inhibition of antigen-presenting cell function and the suppression of production of proinflammatory cytokines and chemokines. 105, 106 There were no differences in plasma IL-10 between patients with FS and controls. 57 Several animal studies and clinical observations suggest an anticonvulsant effects of IL-10. One report showed protective effects of IL-10 against the development of epileptiform activity evoked by transient episodes of hypoxia in rat hippocampal slices. 107 In hyperthermia-induced seizures of immature rats, the seizure threshold temperature in IL-10 treated rats was significantly higher than in the saline treated controls. 108 Furthermore, the frequencies of the IL-10 592C allele and 1082A/-819C/-592C haplotype, which have been reportedly associated with increased production of IL-10, 109 were significantly lower in patients suffering from FS as compared to healthy controls. 108 
Fibroblast growth factor (FGF)
FGF-1 and FGF-2 are members of the FGF family that regulate cell proliferation, migration, differentiation, and survival. 110, 111 After a single episode of amygdala kindling, FGF-2 mRNA levels were increased in hippocampus, neocortex, and hypothalamus. 112 In chronic electroconvulsive shock treated rats, significantly elevated FGF-2 was found in the frontal and rhinal cortex, which postictally peaked at 20 h and remained significantly elevated for up to 72 h. 113 However, the role of FGF-2 in epileptogenesis is contested with various studies suggesting conflicting roles. Fetal hippocampal CA3 cell grafts enriched with FGF-2 and brainderived neurotrophic factor (BDNF) suppressed aberrant mossy fiber sprouting in the injured middle-aged hippocampus. 114 Moreover, supplementation of FGF-2 and BDNF in the hippocampus lesioned by prolonged seizures limited damage and reduced spontaneous seizures. 115 However, transgenic mice with increased FGF-2 expression displayed increased susceptibility to kainateinduced seizures, but reduced neuronal death. 116 Other studies found that FGF-2 was able to alter the electrical activity of hippocampal neurons and to cause seizures 117 while intraperitoneal injection of FGF-1 in kainic acid treated rats significantly decreased tonic-clonic convulsions and mortality. 118 Taken together, these results indicate that FGF-2 is implicated in both seizure-induced plasticity and seizure susceptibility in animal models.
There are very few clinical studies on FGF in human epilepsy. In one group of corticectomy specimens from epileptic patients, including focal cortical dysplasia, tubers of tuberous sclerosis, and gliotic lesions, FGF-2 expression was observed in abnormal neuroglial cells, including balloon cells and dysplastic neurons, and reactive astrocytes. 119 
IL-3, IL-8, LIF and interferon-g
Intraventricular administration of high doses of hr-IL-3 in rats produced 3-5 Hz spike-wave complexes that were associated with episodes of arrest. 120 IL-8 concentration in serum and CSF of patients with refractory epilepsy was significantly increased after seizures, including focal, generalized tonic-clonic, myoclonic, atypical absence, and typical absence seizures. 78 After seizures in rat epilepsy models, leukemia inhibitory factor (LIF) was found to be up-regulated in the hippocampus, neocortex, dentate gyrus, and meninges; 11, 66 LIF receptor mRNA was induced in the hippocampus and neocortex. 11, 66 Interferon-g was associated with the development of limbic seizures in West Nile virus infected mice and absence of interferon-g during the development of the CNS may cause intracerebral alterations resulting in enhanced tolerance to epileptic stimuli. 121 
Conclusion
Generally, limited information is available on the expression and function of cytokines, apart from IL-1b, IL-6 and TNFa, in seizure and epilepsy. However, the experimental data suggest a postictal activation of cytokine networks rather than the release of single cytokines. In particular, the anticonvulsive role of IL-10 and the proconvulsive role of FGF-2 appear to merit further studies.
Influence of cytokines on blood-brain-barrier (BBB) permeability in epilepsy
In human and animal studies of epilepsy, BBB failure has been shown before, during, and after seizures. The underlying mechanisms for this effect are thought to be complex and have yet to be elucidated in detail. [122] [123] [124] [125] [126] On one hand, the etiology of epilepsy, e.g. stroke, traumatic brain injury, or central nervous system infections, may result in compromised BBB function. [127] [128] [129] [130] On the other hand, epileptic seizures by themselves cause transient changes in the functional and structural properties of the BBB. 124, 131 Additionally, the intrinsic inflammation induced by seizures may also lead to enhanced BBB permeability. Disruption of BBB permeability is a possible pathway for cytokines influencing seizures and epilepsy. Several studies revealed BBB 'failure' after administration of IL-1, IL-6, TNFa, and interferon-g. [132] [133] [134] A recent study reported that intravenous administration of IL-1Ra exhibited significant reduction of SE intensity and BBB damage in the rat. 135 Of note, in a mouse model of epilepsy induced by pilocarpine, Fabene et al., found that leukocyte-endothelial interactions were altered by seizures and played an important role in BBB damage and seizure generation. 136 The exact role of altered BBB permeability in the development and course of epilepsy is not well defined. However, a series of studies have supported the views that transient openings of the BBB facilitate both behavioral and electrographic seizures and may establish a link between the systemic immune system and the epileptogenic zone.
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Conclusion
A growing body of evidence suggests that there is an array of cytokines involved in epilepsy. These substances are activated by seizures, but their precise role in epilepsy is not yet clear. Most studies have been focused on three cytokines: IL-1b, IL-6 and TNFa. Levels of these substances increase quickly after either generalized tonic-clonic or complex partial seizures and return to baseline after varying time intervals. Seizures not only induce the expression of cytokines in the brain but also change peripheral cytokine levels. In recent years, the vagus nerve has been found to play an important role in signaling the immune status to the brain or vice versa. 138, 139 Changes in peripheral cytokine levels, such as IL-6 and IL-8, were reported after vagus nerve stimulation in patients with refractory epilepsy. [140] [141] [142] Therefore, future studies are warranted to characterize the impact of the vagus nerve on the relationship between seizures and peripheral cytokines. Available studies highlight the dichotomous role of IL-1b, IL-6 and TNFa in epileptogenesis. These molecules have demonstrated pro-and anticonvulsive properties in different animal studies. The difficulty to extrapolate the results of these studies to human epilepsies remains. This is because studies in epileptic patients are often limited to cytokine detection in blood or CSF, and only few reports study brain specimens obtained from surgical candidates or autopsies. There is a great need for further studies regarding the role(s) of cytokines in human epilepsy. A key point to be addressed in further studies is whether, and to what extent, endogeneous cytokine release is relevant for the process of epileptogenesis and if this process can be prevented by immunomodulatory treatment.
